Tag: anti-tumor necrosis factor
Dermatology Risks Are Likely Different for JAK Inhibitors
NEW ORLEANS — All but one Janus kinase (JAK) inhibitor with dermatologic indications carries a black box...
Better Together for Ulcerative Colitis
CHARLOTTE, NC — People with moderate-to-severe ulcerative colitis benefit from stronger treatment from the start — a...
Anti-TNF Therapy After 24 Weeks of Pregnancy Appears Safe: Study
Continuing anti-tumor necrosis factor (anti-TNF) therapy after 24 weeks of pregnancy is associated with a lower likelihood...
Hope Shines Bright for Hidradenitis Suppurativa Treatments
Additional hidradenitis suppurativa (HS) treatments could be on the horizon with the news that both secukinumab and...
Filgotinib Reduces Flare Risk in Uveitis in Phase 2 Study
GHENT, Belgium – Filgotinib (Jyseleca), a Janus kinase (JAK) inhibitor, reduced the risk of flare after withdrawal...
Olokizumab Proves Noninferior to Adalimumab for RA
The investigational IL-6 inhibitor olokizumab fared better than placebo and was noninferior to the tumor necrosis factor...